

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

CanSino Biologics Inc.
康希諾生物股份公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock code: 6185)

VOLUNTARY ANNOUNCEMENT
OBTAINMENT OF THE PIC/S GMP CERTIFICATE

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the manufacturing site for the Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197) (the “**MCV4**”) and the 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/TT) (the “**PCV13i**”) has passed the Pharmaceutical Inspection Co-Operation Scheme (the “**PIC/S**”) Good Manufacturing Practice (the “**GMP**”) compliance inspection conducted by the Malaysia National Pharmaceutical Regulatory Agency (the “**NPRA**”). The Company has recently been granted a GMP certificate by NPRA.

PIC/S is an internationally recognized authority for pharmaceutical inspection and certification, comprising drug regulatory agencies from dozens of countries. It implements unified standards for GMP inspection and certification of medicinal products for human and veterinary use. GMP compliance inspection is one of the prerequisites for drug registration and approval. On a voluntary basis, PIC/S member countries and participating authorities mutually recognize GMP compliance inspections.

The obtainment of the PIC/S GMP certificate signifies that the Company’s manufacturing and quality management systems comply with PIC/S GMP standards, which will facilitate the advancement of the drug registration and marketing processes for MCV4 and PCV13i in Malaysia and other PIC/S member countries.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
CanSino Biologics Inc.
Xuefeng YU
Chairman

Hong Kong, March 5, 2026

As of the date of this announcement, the board of directors of the Company comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO and Ms. Jing WANG as executive Directors, Mr. Chi Shing LI as a non-executive Director, and Mr. Yiu Leung Andy CHEUNG, Mr. Man CHO and Ms. Xuefeng JI as independent non-executive Directors.